Supplementary_material.docx (231.12 kB)

Supplementary figure 1. Per-patient all-cause and treatment-related grade 3/4 AE costs over 42 months

figure

posted on 2022-01-12, 12:02 authored by Daniel M. Geynisman, Ella X. Du, Xiaoran Yang, Selvam R. Sendhil, Viviana Del Tejo, Keith A. Betts, Stephen Huo

(a) Grade 3/4 AE costs, all treated population; (b) Grade 3/4 AE costs, all treated patients with intermediate/poor risk.

Funding

Bristol-Myers Squibb

History

Usage metrics

Future Oncology

Keywords

advanced/metastatic renal cell carcinoma temporal trend sunitinib nivolumab plus ipilimumab adverse events CheckMate 214 costs Cancer Therapy (excl. Chemotherapy and Radiation Therapy)

Licence

CC BY-NC-ND 4.0

Supplementary figure 1. Per-patient all-cause and treatment-related grade 3/4 AE costs over 42 months

Funding

Bristol-Myers Squibb

History

Usage metrics

Categories

Keywords

Licence

Exports